Fig. 2From: The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid reviewSummary of results for efficacy and safety outcomes. Abbreviations: HR hazard ratio, IV intravenous, RR risk ratio, SC subcutaneous. 1Due to imprecision, 2drop-out rate of 37%, 3due to high risk of bias, 4due to high risk of bias and imprecisionBack to article page